A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 186 800 KRW -1.99% Market Closed
Market Cap: 10.3T KRW

ABL Bio Inc
Total Other Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ABL Bio Inc
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Total Other Income
â‚©156.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Total Other Income
-â‚©96B
CAGR 3-Years
-52%
CAGR 5-Years
N/A
CAGR 10-Years
-5%
SK Bioscience Co Ltd
KRX:302440
Total Other Income
-â‚©4.2B
CAGR 3-Years
N/A
CAGR 5-Years
-22%
CAGR 10-Years
N/A
V
Voronoi Inc
KOSDAQ:310210
Total Other Income
-â‚©65.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Total Other Income
-â‚©577.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-28%
Alteogen Inc
KOSDAQ:196170
Total Other Income
â‚©368.3m
CAGR 3-Years
-49%
CAGR 5-Years
21%
CAGR 10-Years
49%
No Stocks Found

ABL Bio Inc
Glance View

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
15 915.23 KRW
Overvaluation 91%
Intrinsic Value
Price
A

See Also

What is ABL Bio Inc's Total Other Income?
Total Other Income
156.1m KRW

Based on the financial report for Jun 30, 2025, ABL Bio Inc's Total Other Income amounts to 156.1m KRW.

Back to Top